Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Revlimid Now Approved for Follicular Lymphoma and Marginal-Zone Lymphoma

August 2019 Vol 5 No 4

In May 2019, the FDA approved the new combination of Revlimid (lenalidomide; from Celgene) plus Rituxan (rituximab; from Genentech) for the treatment of patients with follicular lymphoma or marginal-zone lymphoma. Both drugs were previously approved for different cancer types.

This new approval was based on the results of 2 clinical trials in patients with relapsed or refractory follicular lymphoma or with marginal-zone lymphoma who received Revlimid plus Rituxan or placebo plus Rituxan.

The average time without disease progression was 39.4 months with Revlimid plus Rituxan versus 14.1 months with placebo plus Rituxan. Overall, 80% of the patients with follicular lymphoma responded to Revlimid plus Rituxan therapy versus 55.4% of patients who responded to placebo plus Rituxan; these rates were 65% versus 44%, respectively, in ­patients with marginal-zone lymphoma.

Recommended For You